Clinical trials: Active Population
Glaucoma and Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
The purpose of this study is to investigate the safety and efficacy of up to three concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as monotherapy and as adjunctive therapy (DE-117 ophthalmic…
- Trial name
- NCT01654484
- Testing
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Asthma
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus…
- Trial name
- TRIMARAN (NCT02676076)
- Testing
- CHF 5993 100/6/12.5, CHF 1535 100/6 µg
- Where
- Germany
- Volunteers
- 1,155 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Essential Hypertension
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of…
- Trial name
- NCT00758524
- Testing
- LCI699, Eplerenone
- Where
- United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Anemia, Renal Insufficiency, Chronic
Maintenance Treatment of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).
- Trial name
- MIYABI HD-M (NCT03543657)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 53 sites in Japan
- Volunteers
- 229 people
- Sponsor
- Bayer
Hypertension, Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Trial name
- VALENCIA (NCT01368536)
- Testing
- Valturna, Amlodipine, Chlorthalidone
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 975 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Contraception
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50 years of age who request oral contraceptive…
- Trial name
- NCT00754065
- Testing
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
- Where
- 59 sites in United States, Canada
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Bayer
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are…
- Trial name
- CULTIVATE (NCT04173273)
- Testing
- Etrasimod
- Where
- 510 sites in United States, Argentina and 39 more
- Volunteers
- 379 people
- Sponsor
- Pfizer
HBV
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
This is a phase 1, randomized, parallel-group, single-center study in healthy adult subjects. The study will be conducted in two parts sequentially: Part 1 is an open-label, two-arm, active-controlled design to evaluate the PK…
- Trial name
- NCT03239353
- Testing
- Entecavir
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aucta Pharmaceuticals, Inc
Chronic Idiopathic Urticaria
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1…
- Trial name
- NCT05774639
- Testing
- Omalizumab Injection, Xolair Prefilled Syringe
- Where
- 6 sites in United States, India and 1 more
- Volunteers
- 600 people
- Sponsor
- Kashiv BioSciences, LLC
Crohn Disease
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe…
- Trial name
- ICONIC-CD (NCT07196722)
- Testing
- Icotrokinra
- Where
- 395 sites in United States, Argentina and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Janssen Research & Development, LLC
Epilepsy
Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
Zonisamide (Zonegran) and sodium valproate (Epilim) are both medicines approved to treat epilepsy. The purpose of this study is to find out the extent to which zonisamide may affect memory and concentration, compared to sodium…
- Trial name
- NCT00713622
- Testing
- Zonisamide, Sodium valproate
- Where
- 2 sites in Austria, Finland
- Volunteers
- 2 people
- Sponsor
- Eisai Limited
Depression, Bipolar I Disorder
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- 3112 Ped BPD (NCT04777357)
- Testing
- Cariprazine
- Where
- 81 sites in United States, Puerto Rico and 1 more
- Volunteers
- 380 people
- Sponsor
- AbbVie
Chronic Hepatitis c
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic…
- Trial name
- NCT01903278
- Testing
- PEG-IFN-SA /RBV, Pegasys /RBV
- Where
- 41 sites in China
- Volunteers
- 719 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Osteoarthritis
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
The purpose of this study is to compare the safety and effectiveness of an investigational drug and an approved drug in the treatment of osteoarthritis of the knee and hip.
- Trial name
- NCT00092768
- Testing
- MK0663, etoricoxib, Comparator: celecoxib
- Volunteers
- 500 people
- Sponsor
- Organon and Co
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
- Trial name
- NCT04032158
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Poliomyelitis
A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
The purpose of the study is to evaluate safety and immunogenicity of inactivated poliomyelitis vaccine based on Sabin strain (LBVC) in healthy infants to select optimal dose of LBVC as well as to demonstrate the lot-to-lot…
- Trial name
- NCT03169725
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strain), Inactivated Poliomyelitis Vaccine (Salk strain)
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 1,417 people, healthy volunteers welcome
- Sponsor
- LG Chem
Anthrax
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
- Trial name
- NCT01770743
- Testing
- AV7909, BioThrax
- Where
- 4 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Crohn's Disease
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
A 26 week maintenance study of CDP870 in Crohn's disease
- Trial name
- NCT00152425
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 392 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.